查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179529

银屑病治疗药物市场:按药物类别、类型和给药途径分类:全球机会分析和行业预测，2021-2031 年

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 242 Pages | 商品交期: 2-3个工作天内

价格

牛皮癣是一种皮肤病，会导致皮肤细胞的生长速度比正常情况快 10 倍。

这会导致皮肤变成覆盖着白色鳞屑的凹凸不平的红色斑块。 它们可以出现在任何地方，但最常见于头皮、肘部、膝盖和下背部。 牛皮癣不会在人与人之间传播。 但有时它发生在同一个家庭中。 牛皮癣通常发生在成年早期。 大多数人只会在几个地方出现症状。 在严重的情况下，它可能会覆盖大部分身体。 牛皮癣可以终生治愈或复发。 然而，有许多治疗方法。 有些可以减缓新皮肤细胞的生长，而另一些则可以舒缓瘙痒和干燥的皮肤。 您的医生会根据皮疹的大小、皮疹在身体上的位置、年龄、一般状况和患者的其他情况，为您的患者选择正确的治疗方案。 常见的治疗方法包括类固醇乳膏、干性皮肤保湿剂煤焦油（一种治疗头皮牛皮癣的常见药物，有乳液、乳霜、泡沫、洗髮水和沐浴液）、维生素 D 基乳膏和软膏，以及维甲酸乳膏等。

推动全球银屑病治疗市场增长的主要因素是老年人口的增长、斑块和银屑病关节炎患病率的增加、优惠的报销政策以及生物製剂处方量的增加。例如 此外，人们对市场上可用的各种治疗方法的认识不断提高，进一步推动了市场的增长。 然而，在预测期内，与治疗成本上升相关的药物引起的健康风险正在抑制银屑病治疗市场的增长。 相反，新生物製剂和新管道药物的开发不断增加，未开发的新兴国家的高增长潜力有望为市场参与者提供有利可图的机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析
  • 专利情况

第 4 章银屑病药物市场:按治疗类别分类

  • 概览
    • 市场规模和预测
  • TNF-ALPHA 抑製剂
    • 主要市场趋势、增长因素和机遇
    • 各地区的市场规模和预测
    • 市场分析:按国家/地区分类
  • 白细胞介素抑製剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类
    • 白细胞介素抑製剂银屑病药物市场:按分销渠道
      • 医院药房市场规模和预测:按地区
      • 药店和零售药店市场规模和预测:按地区
      • 在线提供商市场规模趋势和预测:按地区
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类

第 5 章银屑病药物市场:按类型

  • 概览
    • 市场规模和预测
  • 斑块状银屑病
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类
  • 银屑病关节炎
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类

第 6 章银屑病药物市场:按给药途径

  • 概览
    • 市场规模和预测
  • 口语
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类
  • 父母代理人
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类
  • 外部代理
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测:按地区
    • 市场分析:按国家/地区分类

第 7 章银屑病药物市场:按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测:按药物类别
      • 按白细胞介素抑製剂划分的北美银屑病药物市场:按分销渠道
    • 北美市场规模和预测:按类型
    • 北美市场规模和预测:按给药途径
    • 北美市场规模和预测:按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测:按药物类别
      • 按白细胞介素抑製剂划分的欧洲银屑病药物市场:按分销渠道
    • 欧洲市场规模和预测:按类型
    • 欧洲市场规模和预测:按给药途径
    • 欧洲市场规模和预测:按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机会
    • 按药物类别划分的亚太市场规模和预测
      • 按白介素抑製剂划分的亚太地区银屑病药物市场:按分销渠道
    • 亚太市场规模和预测:按类型
    • 按给药途径划分的亚太地区市场规模和预测
    • 亚太地区的市场规模和预测:按国家/地区分类
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 银屑病药物市场规模和预测:按药物类别
      • 白细胞介素抑製剂的 LAMEA 银屑病药物市场:按分销渠道
    • LAMEA 市场规模和预测:按类型
    • LAMEA 市场规模和预测:按给药途径
    • LAMEA 市场规模和预测:按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • Abbvie Inc.
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Johnson and Johnson
  • LEO Pharma
  • Novan Inc.（EPI Health LLC）
  • Novartis AG
  • Pfizer Inc.
  • Viatris Inc.（Mylan NV）
Product Code: A03405

Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on scalp, elbows, knees, and lower back. Psoriasis cannot pass from person to person. It does sometimes happen in members of the same family. Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, it can cover large parts of the body. The patches can heal and then come back throughout a person's life. However, there are many treatments. Some slow the growth of new skin cells, and others relieve itching and dry skin. Doctor selects a treatment plan that is right for patient based on the size of rash, where it is on the body, age, overall health, and other things of patients. Common treatments include steroid creams, moisturizers for dry skin coal tar (a common treatment for scalp psoriasis available in lotions, creams, foams, shampoos, and bath solutions), vitamin D-based cream or ointments, and Retinoid creams.

Major factors that drive growth of the global psoriasis therapeutics market include increase in geriatric population, growth in prevalence of plaque and psoriatic arthritis, favorable reimbursement policies, and rise in prescription volume of biological products. In addition, rise in awareness among people regarding different treatments available in the market further propel the market growth. However, health risks posed, owing to medication along with high costs of therapies restrain growth of the psoriasis therapeutics market during the forecast period. Conversely, increase in development of new biologics and novel pipeline drugs and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities to the market players.

The psoriasis therapeutics market is segmented on the basis of drug class, type, route of administration, end user, and region. According to drug class, the market is categorized into TNF-alpha inhibitors, interleukin inhibitors, and others. Interleukin inhibitors further segmented by distribution channel, including hospital pharmacies, drug stores & retail pharmacies, and online providers. On the basis of type, it is divided into plaque psoriasis, psoriatic arthritis, and others. On the basis of route of administration, it is classified into oral, topical, and parenteral. Furthermore, regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: AbbVie Inc., Amgen Inc., Bausch Health Companies Inc, Eli Lilly and Company, Johnson & Johnson (J&J), Leo Pharma A/S, Novan, Inc., Novartis AG, Pfizer Inc., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the psoriasis therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • TNF-alpha Inhibitors
  • Interleukin Inhibitors
    • Distribution Channel
    • Hospital Pharmacies
    • Drug Stores and Retail Pharmacies
    • Online Providers
  • Others

By Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Rest Of Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbvie Inc.
    • Amgen Inc.
    • Bausch Health Companies Inc.
    • Eli Lilly and Company
    • Johnson and Johnson
    • LEO Pharma
    • Novan Inc. (EPI Health LLC)
    • Novartis AG
    • Pfizer Inc.
    • Viatris Inc. (Mylan NV)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 TNF-alpha Inhibitors
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Interleukin Inhibitors
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
      • 4.3.4.1 Hospital Pharmacies Market size and forecast, by region
      • 4.3.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
      • 4.3.4.3 Online Providers Market size and forecast, by region
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Plaque Psoriasis
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Psoriatic Arthritis
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Oral
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Parenteral
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Topical
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
      • 7.2.2.1 North America Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.2.3 North America Market size and forecast, by Type
    • 7.2.4 North America Market size and forecast, by Route of Administration
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Class
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Class
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Class
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
      • 7.3.2.1 Europe Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.3.3 Europe Market size and forecast, by Type
    • 7.3.4 Europe Market size and forecast, by Route of Administration
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Class
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Class
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Class
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Class
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Class
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Class
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
      • 7.4.2.1 Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.4.3 Asia-Pacific Market size and forecast, by Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Class
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Class
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Drug Class
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Drug Class
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Class
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Class
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
      • 7.5.2.1 LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.5.3 LAMEA Market size and forecast, by Type
    • 7.5.4 LAMEA Market size and forecast, by Route of Administration
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Class
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Class
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Class
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Class
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Amgen Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Johnson and Johnson
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 LEO Pharma
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novan Inc. (EPI Health LLC)
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Novartis AG
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Pfizer Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Viatris Inc. (Mylan NV)
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 2. PSORIASIS THERAPEUTICS MARKET, FOR TNF-ALPHA INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PSORIASIS THERAPEUTICS MARKET FOR TNF-ALPHA INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. PSORIASIS THERAPEUTICS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. PSORIASIS THERAPEUTICS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 7. PSORIASIS THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. PSORIASIS THERAPEUTICS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. PSORIASIS THERAPEUTICS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 13. PSORIASIS THERAPEUTICS MARKET, FOR PLAQUE PSORIASIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. PSORIASIS THERAPEUTICS MARKET FOR PLAQUE PSORIASIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. PSORIASIS THERAPEUTICS MARKET, FOR PSORIATIC ARTHRITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. PSORIASIS THERAPEUTICS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 20. PSORIASIS THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. PSORIASIS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. PSORIASIS THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. PSORIASIS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. PSORIASIS THERAPEUTICS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. PSORIASIS THERAPEUTICS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. PSORIASIS THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. U.S. PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 33. U.S. PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. U.S. PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. FRANCE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 52. UK PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 53. UK PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. UK PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 55. ITALY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. ITALY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. ITALY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 72. CHINA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 73. CHINA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. CHINA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 75. INDIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 76. INDIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 103. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 104.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 105.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 106.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 107.ABBVIE INC.: NET SALES,
  • TABLE 108.ABBVIE INC.: KEY STRATERGIES
  • TABLE 109.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 110.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 111.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 112.AMGEN INC.: NET SALES,
  • TABLE 113.AMGEN INC.: KEY STRATERGIES
  • TABLE 114.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 115.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 116.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 117.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 118.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 119.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 120.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 121.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 122.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 123.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 124.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 125.JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 126.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 127.JOHNSON AND JOHNSON: NET SALES,
  • TABLE 128.JOHNSON AND JOHNSON: KEY STRATERGIES
  • TABLE 129.LEO PHARMA: COMPANY SNAPSHOT
  • TABLE 130.LEO PHARMA: OPERATING SEGMENTS
  • TABLE 131.LEO PHARMA: PRODUCT PORTFOLIO
  • TABLE 132.LEO PHARMA: NET SALES,
  • TABLE 133.LEO PHARMA: KEY STRATERGIES
  • TABLE 134.NOVAN INC. (EPI HEALTH LLC): COMPANY SNAPSHOT
  • TABLE 135.NOVAN INC. (EPI HEALTH LLC): OPERATING SEGMENTS
  • TABLE 136.NOVAN INC. (EPI HEALTH LLC): PRODUCT PORTFOLIO
  • TABLE 137.NOVAN INC. (EPI HEALTH LLC): NET SALES,
  • TABLE 138.NOVAN INC. (EPI HEALTH LLC): KEY STRATERGIES
  • TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 142.NOVARTIS AG: NET SALES,
  • TABLE 143.NOVARTIS AG: KEY STRATERGIES
  • TABLE 144.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 145.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 146.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 147.PFIZER INC.: NET SALES,
  • TABLE 148.PFIZER INC.: KEY STRATERGIES
  • TABLE 149.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
  • TABLE 150.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
  • TABLE 151.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
  • TABLE 152.VIATRIS INC. (MYLAN NV): NET SALES,
  • TABLE 153.VIATRIS INC. (MYLAN NV): KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PSORIASIS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.PSORIASIS THERAPEUTICS MARKET,2021-2031
  • FIGURE 3.PSORIASIS THERAPEUTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PSORIASIS THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.PSORIASIS THERAPEUTICS MARKET,BY DRUG CLASS,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TNF-ALPHA INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 18.PSORIASIS THERAPEUTICS MARKET,BY TYPE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PLAQUE PSORIASIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PSORIATIC ARTHRITIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 22.PSORIASIS THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ORAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PARENTERAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF TOPICAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 26.PSORIASIS THERAPEUTICS MARKET BY REGION,2021
  • FIGURE 27.U.S. PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.UK PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 53.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 54.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 56.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 57.LEO PHARMA.: NET SALES ,($MILLION)
  • FIGURE 58.NOVAN INC. (EPI HEALTH LLC).: NET SALES ,($MILLION)
  • FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 61.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)